Scale with confidence today. Exit with strength tomorrow.
We help mid-market healthtech and pharmacy companies align brand, story, and strategy. The result: buyers see value, not risk.
As seen on
Ready to see how buyers at HLTH 2025 value you?
Your Exit Readiness Scorecard shows how your company performs across five buyer signals: clarity, proof, positioning, story, and presence.
Then, schedule your complimentary Exit Readiness Diagnostic during HLTH 2025 to review your results with Dr. Roxie and Emily.
Great companies get undervalued every day.
You can have strong revenue, loyal customers, and proven outcomes — and still get discounted when it’s time to raise, recapitalize, or exit. Buyers don’t pay for innovation alone. They pay for clarity, credibility, and proof that your growth story is built to scale. If your positioning is fuzzy, your messaging fragmented, or your value unclear, you’re already leaving money on the table.
From growth to valuation. And every move in between.
We align your commercial, brand, and investor strategies into one scalable system.
Exit Readiness Sprint™
A 90-day sprint to transform your positioning, messaging, and corporate story into buyer-ready assets.
Premium Acquisition Sprint™
Sharpen your valuation story before diligence begins. Craft the narrative and proof buyers reward with premium multiples.
12-Month Growth Engine Partnership
Embed LDNA as your fractional growth partner to unify marketing, brand, and sales engines that scale traction and value.
We turn clarity into enterprise value.
Legacy DNA is a healthcare growth firm specializing in commercialization, valuation strategy, and brand transformation for healthtech and pharmacy leaders.
Our proprietary frameworks help you:
Build a defensible market position that earns premium multiples
Clarify your story so buyers, partners, and investors see your worth
Connect growth performance to measurable valuation outcomes
HLTH 2025: What buyers are really thinking
We’re pulling back the curtain on what separates healthtech companies that earn premium exits from those that don’t.
5 Hard Truths Exit Buyers Won’t Tell You
Most CEOs lose millions because they don’t see what buyers really value.
The #1 Reason Healthtech Companies Fail to Scale
High burn isn’t momentum — it’s fragility. See how efficient growth drives higher multiples.
What Makes a Healthtech Legend? 3 Traits That Command Premium Multiples
Clarity. Proof. Discipline. Learn the three traits buyers reward.
“We had something good. Legacy DNA made it better — and then some.”
— Dr. Stephen Vogt, Founder & CEO, BioPlus Specialty Pharmacy
Proof that compounds into valuation
When BioPlus partnered with Legacy DNA, they were respected but nearly invisible in a crowded specialty pharmacy market.
13 consecutive quarters of growth
Revenue grew from $750M → $2B
Gross profit up 202%
Two premium exits: Nautic Partners → Elevance Health